Core Viewpoint - The company will present clinical data for its next-generation fully human anti-CTLA-4 antibody, HBM4003, in combination with Tislelizumab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to October 21, 2025 [1] Company Summary - The company is scheduled to announce its Phase II clinical data for HBM4003 during a significant oncology conference [1] - The focus of the clinical data presentation will be on the treatment of MSS mCRC, indicating the company's commitment to advancing cancer therapies [1] Industry Summary - The announcement aligns with ongoing developments in the oncology sector, particularly in the area of immunotherapy for colorectal cancer [1] - The ESMO annual meeting serves as a key platform for showcasing advancements in cancer treatment, highlighting the importance of such presentations for industry stakeholders [1]
和铂医药-B(02142.HK)：于2025年ESMO大会公布HBM4003联合替雷利珠单抗治疗微卫星稳定型转移性结直肠癌的II期临床数据